Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651835 | 0.83 | STS (0.42) | USP30GPR119ABL1RIN1RORC | |
| SCHEMBL30324594 | 0.82 | USP30 (0.43) | USP30GPR119ABL1RIN1MEN1 | |
| SCHEMBL16662462 | 0.78 | IDO1 (0.41) | USP30GPR119NAMPTNR1H2AOC3 | |
| SCHEMBL4487414 | 0.75 | MEN1 (0.47) | USP30GPR119MEN1ALDH1A1KMT2A | |
| SCHEMBL21381625 | 0.74 | HSD11B1 (0.48) | USP30ABL1RIN1MEN1ALDH1A1 | |
| SCHEMBL1528737 | 0.74 | HDAC1 (0.42) | USP30ABL1RIN1NR1H2MEN1 | |
| SCHEMBL2882463 | 0.73 | KDM4E (0.51) | USP30GPR119NAMPTMEN1KMT2A | |
| SCHEMBL18228070 | 0.72 | GPR119 (0.53) | GPR119NAMPTMEN1ALDH1A1MAPT | |
| SCHEMBL22557180 | 0.72 | MEN1 (0.54) | MEN1ALDH1A1KMT2A | |
| SCHEMBL16662147 | 0.72 | LMNA (0.47) | GPR119ABL1RIN1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | USP30 2223/4885GPR119 195/4885ABL1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.